Agenda Weber

Agenda Weber

No te pierdas nuestros próximos eventos

newsRARE Vol. 7

Políticas de fomento y acción sobre enfermedades raras

Número de publicaciones

0

Revistas

0

Colaboraciones

0

Libros

0

Artículos

0

Comunicaciones

0

Informes

Publicaciones destacadas

Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against IL-23 Targeted Therapies for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons (MAIC)

Strategic discussion on funding and access to therapies targeting rare diseases in Spain: an expert consensus paper

Cost-Per-Responder Analysis of Bimekizumab (IL-17A/F inhibitor) against IL-17A and IL-12/23 Targeted Therapies for Psoriatic Arthritis in Spain, based on Matching-Adjusted Indirect Comparisons (MAIC)

Escriba su búsqueda